What is Clinical Research and Trial Platforms?
Conducting rigorous clinical trials is essential for evaluating the safety and efficacy of new cancer therapies, screening tests, and prevention approaches before they can be approved for widespread use. Novel clinical trial designs and research platforms are continuously being developed to accelerate this process.
Innovations in clinical research include enrichment strategies selecting patients most likely to respond, adaptive trials modifying parameters based on interim data, master protocols evaluating multiple therapies simultaneously, and platform trials rapidly screening multiple candidate treatments. These approaches aim to increase trial efficiency, minimize patient burden, and identify optimal treatments faster.
NFCR's Current Early Detection & Intervention Focus
A little over 2 million new cancer cases are expected to be diagnosed in the US in 2024 – 20% of new cancer diagnoses come from cancer survivors. One of NFCR’s current focuses is to conduct more research on early cancer detection and early-stage cancer intervention and treatment. We are supporting a group of leading-edge scientists pioneering and investigating innovative approaches to stop cancers at their early stage, such as stage zero, and to detect them before new cancer happens.
Our goal is to reduce cancer incidences and increase cancer survivors. Through a focus on the detection and eradication of the first cancer cell, we can stop cancer before it starts!
NFCR IMPACTS IN EARLY DETECTION AND INTERVENTION RESEARCH
- NFCR has funded research on biomarkers and imaging techniques to improve early detection of cancer, leading to advances like the discovery of altered methylation patterns in precancerous cells.
- Through its public education and awareness efforts, NFCR promotes prevention behaviors like healthy eating, exercise, and recommended cancer screenings that can reduce cancer risk and incidence.
- The Foundation provides funding for chemoprevention research investigating the effectiveness of natural compounds (e.g. antioxidants) and drugs to prevent cancer, furthering the development of risk-reducing options.
NFCR IMPACTS IN CLINICAL RESEARCH AND TRIAL PLATFORMS RESEARCH
- NFCR supports the development and implementation of innovative clinical trial designs that accelerate the testing of promising cancer therapies.
- Through its collaborative networks, NFCR helps connect researchers with clinical trial resources and expertise, facilitating the translation of laboratory discoveries into clinical studies.
- NFCR funds projects that aim to improve patient participation in clinical trials, particularly focusing on underrepresented populations.
NFCR-Supported Researchers Working on Clinical Research and Trial Platforms
Manijeh Goldberg, Ph.D.
University of Massachusetts
Cesare Spadoni, Ph.D., M.B.A.
University of London
Ronald A. DePinho, M.D.
University of Texas MD Anderson Cancer Center
Yung-Chi Cheng, Ph.D.
Yale University
Learn More About Early Detection & Intervention (Media)
A world without cancer is possible. Help us turn lab breakthroughs into life-saving realities.
5.7 Million+
Donors who have fueled NFCR’s mission
$420 Million+
Invested in high-impact research & programs
36+ Labs & Hundreds of
Nobel Laureates & Key Scientists received NFCR funding, driving breakthrough research
